Hasbak P, Jensen L T, Ibsen H
Department of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, Denmark.
J Hum Hypertens. 2002 Apr;16(4):275-80. doi: 10.1038/sj.jhh.1001365.
The clinical value of renal vein renin sampling (RVRS) as a prognostic tool in the treatment of renovascular hypertension was evaluated. One hundred consecutive patients were included over a 4-year period of time. About half of the patients (49%) were treated interventionally by PTRA (21%), nephrectomy (20%), or vascular surgery (8%). Seven patients (15%) were cured and 15 (32%) had improved (reduction in antihypertensive medicine) after 6 months follow-up, whereas three patients (6%) were cured and 12 (26%) improved after 3-4 years follow-up. Thus, the number of patients cured or improved is comparable with the results from our department reported 20 years ago. However, in the present report, more than twice as many patients were enrolled, leading to double costs. Different indices of lateralisation of the renin generation were calculated for the use in cases of a shrunken kidney (functional share < or =15%). None of the indices clearly discriminated between the patients who did benefit from intervention, and those who did not. The only positive finding was that a peripheral renin concentration lower than 8 mlU/l predicted no effect of intervention, which might lead to the exclusion of 11% of the patients before entering the diagnostic programme. We conclude that the RVRS demands a very restrictive referral pattern if it should be of prognostic value for the blood pressure outcome after intervention. No indices of lateralised renin concentrations proved high predictive value. However, a peripheral renin concentration low in the normal range seems useful as an indicator of no benefit from intervention.
评估了肾静脉肾素采样(RVRS)作为肾血管性高血压治疗预后工具的临床价值。在4年期间纳入了100例连续患者。约一半患者(49%)接受了介入治疗,包括经皮腔内血管成形术(PTRA,21%)、肾切除术(20%)或血管手术(8%)。随访6个月后,7例患者(15%)治愈,15例(32%)病情改善(降压药物用量减少);随访3 - 4年后,3例患者(6%)治愈,12例(26%)病情改善。因此,治愈或病情改善的患者数量与我们科室20年前报告的结果相当。然而,在本报告中,纳入的患者数量是之前的两倍多,导致成本翻倍。计算了肾素生成侧化的不同指标,用于肾萎缩(功能份额≤15%)的病例。没有一个指标能明确区分从干预中获益的患者和未获益的患者。唯一的阳性发现是外周肾素浓度低于8 mlU/l预示干预无效,这可能会使11%的患者在进入诊断程序前被排除。我们得出结论,如果RVRS要对干预后的血压结果具有预后价值,就需要非常严格的转诊模式。没有证据表明肾素浓度侧化指标具有高预测价值。然而,外周肾素浓度处于正常范围较低水平似乎可作为干预无获益的一个指标。